What treatment recommendations are appropriate for a patient with an estimated glomerular filtration rate of 73.9 ml/min/1.73 m² (stage 2 chronic kidney disease)?

Treatment for eGFR 73.9 ml/min/1.73 m²

For a patient with eGFR 73.9 (Stage 2 CKD), treatment depends critically on albuminuria status and comorbidities, but the foundation is identifying and treating the underlying cause, optimizing blood pressure to ≤130/80 mmHg, and initiating kidney-protective medications based on specific indications.

Risk Stratification First

With an eGFR of 73.9 ml/min/1.73 m², you have Stage 2 (G2) CKD. The treatment algorithm hinges entirely on:

• Albuminuria category: Measure urine albumin-to-creatinine ratio (ACR) immediately if not already done
• Presence of diabetes (type 2 specifically)
• Presence of heart failure
• Blood pressure status

Core Pharmacotherapy Based on Clinical Scenario

If Diabetes is Present:

SGLT2 Inhibitor - This is your first-line agent 1, 2:

• Start immediately if ACR ≥200 mg/g (1A recommendation) 1
• Strongly consider even if ACR <200 mg/g (2B recommendation for eGFR 20-45, but reasonable at higher eGFR with diabetes) 1
• Continue even if eGFR drops below 20 during treatment 2

RAS Inhibitor (ACEi or ARB) 1, 2:

• Start if ACR ≥30 mg/g (moderately-to-severely increased albuminuria, A2-A3) - 1B recommendation 2
• Use maximum tolerated dose - the proven benefits came from trials using full doses 1
• Monitor creatinine and potassium within 2-4 weeks 1
• Continue unless creatinine rises >30% within 4 weeks or uncontrolled hyperkalemia develops 1

Nonsteroidal MRA (Finerenone) 1, 2:

• Add if ACR >30 mg/g persists despite maximum RAS inhibitor dose (2A recommendation) 1
• Requires normal baseline potassium and eGFR >25 ml/min/1.73 m² 1
• Can be combined with both RASi and SGLT2i 1

If No Diabetes:

RAS Inhibitor (ACEi or ARB) 2:

• Start if ACR ≥300 mg/g (severely increased albuminuria, A3) - 1B recommendation 2
• Consider if ACR 30-300 mg/g (moderately increased, A2) - 2C recommendation 2
• Consider if ACR <30 mg/g (A1) only for specific indications: hypertension or heart failure with reduced ejection fraction 2

SGLT2 Inhibitor 1, 2:

• Start if ACR ≥200 mg/g - 1A recommendation 1
• Start if heart failure present regardless of albuminuria - 1A recommendation 1
• Consider if ACR <200 mg/g - weaker evidence at this eGFR but reasonable 1

Blood Pressure Management

• Target ≤130/80 mmHg for all CKD patients 1, 3
• If starting or uptitrating RAS inhibitor, recheck BP within 2-4 weeks 1
• Avoid symptomatic hypotension 1

Critical Monitoring Parameters

Within 2-4 weeks of starting/increasing RAS inhibitor 1, 2:

• Serum creatinine (acceptable if rises <30%) 1
• Serum potassium (manage hyperkalemia with potassium-lowering measures rather than stopping drug) 1
• Blood pressure 1

SGLT2 inhibitor monitoring 1:

• Initial eGFR decline is expected and beneficial - do NOT stop therapy for reversible decline 1
• Withhold during prolonged fasting, surgery, or critical illness (ketosis risk) 1

Additional Interventions

• Cardiovascular risk reduction: Statins for hyperlipidemia 3
• Avoid nephrotoxins: NSAIDs, certain antibiotics 3
• Lifestyle: Sodium restriction, protein intake optimization 3
• Screen for CKD complications: Though less common at this eGFR, monitor for anemia, bone disease, acidosis as disease progresses 3

Common Pitfalls

1. Not measuring albuminuria - This is the single most important determinant of treatment intensity at this eGFR level
2. Stopping RAS inhibitor for small creatinine rises - Up to 30% increase is acceptable and predicts long-term benefit 1, 4
3. Underdosing RAS inhibitors - Use maximum tolerated doses 1
4. Delaying SGLT2 inhibitor in diabetic patients - This should be started immediately with appropriate indications 1
5. Not combining therapies - The pillared approach (RASi + SGLT2i + MRA in diabetes) provides additive kidney and cardiovascular protection 1, 5

Nephrology Referral

At eGFR 73.9, referral is not yet indicated unless 6:

• Rapid eGFR decline (>5 ml/min/1.73 m² per year)
• ACR >300 mg/g despite treatment
• Unclear etiology of kidney disease
• Difficulty managing complications